{"schema_version":"1","generated_at":"2026-11-05T06:38:30.610Z","data_as_of":null,"url":"https://www.findmykol.com/kol/yasmin-karimi","json_url":"https://www.findmykol.com/kol/yasmin-karimi/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"yasmin-karimi","name":"Yasmin Karimi","credential":"MD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"institution":"University of Michigan","institution_url":"https://www.findmykol.com/institution/university-of-michigan","city":"Ann Arbor","state":"MI","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1043659857","orcid":"0000-0003-2648-4448","openalex":"A5043944883"},"summary":"Yasmin Karimi is a Hematology physician affiliated with University of Michigan. OpenAlex indexes 125 publications with 901 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":125,"cited_by_count":901,"h_index":13,"latest_activity_year":2026,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT04431635","title":"Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma","phase":"PHASE1","status":"TERMINATED","role":"Overall official","sponsor":"University of Michigan Rogel Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT04431635","trial_url":"https://www.findmykol.com/trial/NCT04431635"}],"source":"trials"},"payments":{"company_count":12,"program_years":{"first":2021,"last":null},"rows_total":46,"shown":3,"withheld":43,"rows":[{"payer":"Genentech","program_year":2025,"amount_usd":298257.5,"payment_count":18,"source_url":"https://openpaymentsdata.cms.gov/search?query=1043659857"},{"payer":"AbbVie","program_year":2025,"amount_usd":197872.24,"payment_count":10,"source_url":"https://openpaymentsdata.cms.gov/search?query=1043659857"},{"payer":"Genmab","program_year":2025,"amount_usd":161727.63,"payment_count":41,"source_url":"https://openpaymentsdata.cms.gov/search?query=1043659857"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1043659857","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial","year":2026,"journal":"Annals of Hematology","source_url":"https://doi.org/10.1007/s00277-026-06798-4","status":"verified"},{"title":"First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma","year":2026,"journal":"HemaSphere","source_url":"https://doi.org/10.1002/hem3.70443","status":"verified"},{"title":"Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2024026830","status":"verified"},{"title":"Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2025029117","status":"verified"},{"title":"NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025","year":2025,"journal":"Journal of the National Comprehensive Cancer Network","source_url":"https://doi.org/10.6004/jnccn.2025.0048","status":"verified"}],"source":"works"},"contact":{"address_1":"1500 E MEDICAL CENTER DR","city":"Ann Arbor","state":"MI","zip":"481095000","phone":"734-936-4000","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1043659857","source":"identity"},"similar":[{"name":"Max Wicha","slug":"max-wicha","institution":"University of Michigan","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/max-wicha","json_url":"https://www.findmykol.com/kol/max-wicha/profile.json"},{"name":"Eva Feldman","slug":"eva-feldman","institution":"University of Michigan","specialty":"Neurology","url":"https://www.findmykol.com/kol/eva-feldman","json_url":"https://www.findmykol.com/kol/eva-feldman/profile.json"},{"name":"Dinesh Khanna","slug":"dinesh-khanna","institution":"University of Michigan","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/dinesh-khanna","json_url":"https://www.findmykol.com/kol/dinesh-khanna/profile.json"},{"name":"Joshua Ehrlich","slug":"joshua-ehrlich","institution":"University of Michigan","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/joshua-ehrlich","json_url":"https://www.findmykol.com/kol/joshua-ehrlich/profile.json"},{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"},{"name":"Jaroslaw Maciejewski","slug":"jaroslaw-maciejewski","institution":"Cleveland Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/jaroslaw-maciejewski","json_url":"https://www.findmykol.com/kol/jaroslaw-maciejewski/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":43,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2020-10-19","provider_certified":"2020-10-19","collected_at":"2026-11-04T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}